Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024

P W Hellings^{1

2

3}, D M Conti^{4

5

6}, X Bertels^{6

7}, V Backer⁸, G Brusselle^{9

10}, E De Corso¹¹, W J Fokkens¹², A T Fox^{13

14}, P Gevaert¹⁵, S Lau¹⁶, G Liva¹⁷, S Palkonen¹⁸, A Papi¹⁹, S Scheire^{6

15}, P Schmid-Grendelmeier^{20

21}, C M E Shire²², P Smith^{23

24}, M T A Teeling²², A Yorgancioglu²⁵, G K Scadding^{26

27}

Affiliations

¹ Department of Otorhinolaryngology, Laboratory of Upper Airways Research, University of Ghent, Ghent, Belgium.
² Department of Microbiology and Immunology, Allergy and Clinical Immunology Research Unit, KU Leuven, Leuven, Belgium.
³ Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
⁴ Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Madrid, Spain.
⁵ Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
⁶ Scientific Expert Team Members, The European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium.
⁷ Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands.
⁸ Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
⁹ Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
¹⁰ Departments of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
¹¹ Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
¹² Department of Otorhinolaryngology, Amsterdam University Medical Centre, Amsterdam, Netherlands.
¹³ Children's Allergy Service, Evelina London Children's Hospital, London, United Kingdom.
¹⁴ Department of Paediatric Allergy, King's College London, London, United Kingdom.
¹⁵ Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
¹⁶ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹⁷ Department of Otorhinolaryngology, School of Medicine, University of Crete, Heraklion, Greece.
¹⁸ European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium.
¹⁹ Respiratory Medicine, Univerity of Ferrara, Ferrara, Italy.
²⁰ Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
²¹ Department of Dermatology, High Altitude Clinic, Medicine Campus Davos-Wolfgang, Davos-Wolfgang, Switzerland.
²² Patient Advisory Board, The European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium.
²³ School of Medicine, Griffith University, Gold Coast, QLD, Australia.
²⁴ Menzies Centre, National Centre for NeuroImmunology and Emerging Disease, Gold Coast, QLD, Australia.
²⁵ Department of Chest Diseases, Celal Bayar University Faculty of Medicine, Manisa, Türkiye.
²⁶ Department of Allergy & Rhinology, Royal National ENT Hospital, London, United Kingdom.
²⁷ Division of Immunity and Infection, University College, London, United Kingdom.

PMID: 40065834
PMCID: PMC11891202
DOI: 10.3389/falgy.2025.1540499

Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024

P W Hellings et al. Front Allergy. 2025.

. 2025 Feb 24:6:1540499.

doi: 10.3389/falgy.2025.1540499. eCollection 2025.

Authors

Affiliations

¹ Department of Otorhinolaryngology, Laboratory of Upper Airways Research, University of Ghent, Ghent, Belgium.
² Department of Microbiology and Immunology, Allergy and Clinical Immunology Research Unit, KU Leuven, Leuven, Belgium.
³ Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
⁴ Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Madrid, Spain.
⁵ Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
⁶ Scientific Expert Team Members, The European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium.
⁷ Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands.
⁸ Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
⁹ Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
¹⁰ Departments of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
¹¹ Otorhinolaryngology Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
¹² Department of Otorhinolaryngology, Amsterdam University Medical Centre, Amsterdam, Netherlands.
¹³ Children's Allergy Service, Evelina London Children's Hospital, London, United Kingdom.
¹⁴ Department of Paediatric Allergy, King's College London, London, United Kingdom.
¹⁵ Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
¹⁶ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹⁷ Department of Otorhinolaryngology, School of Medicine, University of Crete, Heraklion, Greece.
¹⁸ European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium.
¹⁹ Respiratory Medicine, Univerity of Ferrara, Ferrara, Italy.
²⁰ Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
²¹ Department of Dermatology, High Altitude Clinic, Medicine Campus Davos-Wolfgang, Davos-Wolfgang, Switzerland.
²² Patient Advisory Board, The European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium.
²³ School of Medicine, Griffith University, Gold Coast, QLD, Australia.
²⁴ Menzies Centre, National Centre for NeuroImmunology and Emerging Disease, Gold Coast, QLD, Australia.
²⁵ Department of Chest Diseases, Celal Bayar University Faculty of Medicine, Manisa, Türkiye.
²⁶ Department of Allergy & Rhinology, Royal National ENT Hospital, London, United Kingdom.
²⁷ Division of Immunity and Infection, University College, London, United Kingdom.

PMID: 40065834
PMCID: PMC11891202
DOI: 10.3389/falgy.2025.1540499

Abstract

In April 2024, the European Summit "Raising the bar in respiratory care" was organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) in the European Parliament and hosted by Members of the European Parliament Dorien Rookmaker and Mislav Kolakušić. The aim of the Summit was to respond to the need of European patients suffering from chronic respiratory diseases (CRDs) by joining forces with European and global organisations in the management of the epidemics of CRD, recognising the weaknesses of current care models and focussing on collaboration to improve care and prevention. Participants belonging to International and National Societies and Committees from the European Rhinologic Society (ERS), International Rhinologic Society (IRS), Belgian Respiratory Society (BeRS), Global Initiative for Asthma (GINA), Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Alliance against Chronic Respiratory Diseases (GARD), and from the European Federation of Allergy and Airways Diseases Patients Associations (EFA) and the EUFOREA's Patient Advisory Board (PAB) described their vision and action plan to work in partnership to raise the bar in respiratory care. This report summarizes the contributions of the representatives of different European stakeholders in the field of CRDs.

Keywords: EUFOREA; European Parliament; action plan; chronic respiratory diseases; respiratory care.

PubMed Disclaimer

Conflict of interest statement

PH: Unrestricted research grants and/or honoraria for lectures/advisory boards by Novartis, Sanofi/Regeneron, GSK and Viatris. DC: Serves as Academic Manager at the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) and as Review Editor at Frontiers in Allergy, Rhinology Section. XB: Patient Advisory Board & Advocacy Manager, EUFOREA; no personal grants to declare in relation to VB: Has received research grants, participated in advisory boards, and developed pharmaceutical studies for GSK, AstraZeneca, Sanofi, Regeneron, Novartis, MSD, Pharmaxis, ALK Abello, Birk NPC, Chiesi and Menarini. GB: Fees for advisory boards and lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, MSD, Novartis, and Sanofi Regeneron. ED: Received lectures fee and participated to AB for Sanofi, GSK, Regeneron, Astrazeneca. FW: The department of Otorhinolaryngology of the Amsterdam University Medical centre, location AMC received grants for research in Rhinology from: Novartis, EU, GSK, and Sanofi-Aventis. WF received consultation and/or speaker fees from Dianosic, GSK, Novartis, Sanofi-Aventis/Regeneron and Astra. AF: Chair, National Allergy Strategy Group (UK), Chair of Health Advisory Board, Allergy UK, Independent Safety Monitor for Clinical Trials for ALK-Abello, Denmark. PG: Has served as an advisor or speaker or received grant/research support from ALK, GSK, Lilly, Regeneron, Sanofi, and Stallergenes-Greer. SL: received honoraria for lectures and/or participation at advisory boards of Sanofi-Aventis, Allergopharma, ALK, Leo Pharma, Leti, Viatris, Lilly, GSK, DBV during the last 3 years. AP: Alberto Papi declares payments to his institution from Chiesi, AstraZeneca, GlaxoSmithKline and Sanofi; consultancy fees from Chiesi, AstraZeneca, GlaxoSmithKline, Sanofi, Iqvia, Avillion, Moderna, Roche, Regeneron and payment or honoraria for lectures, presentations, speakers’ bureaus, from Chiesi, AstraZeneca, GlaxoSmithKline, Menarini, Zambon, Mundipharma, Sanofi, Avillion, all outside the submitted work. SS: Serves as the Patient Education Manager at EUFOREA. PS-G: Has received grants, personal fees, honoraria, and/or non -financial support from Pfizer Inc., AbbVie, Biomed, Eli Lilly and Company, Galderma, L'Oreal, Janssen, LEO Pharma, Novartis, Pierre Fabre, Sanofi Genzyme, and Thermo Fisher. PS: Has received investigator initiated research funding from Hyloris, GSK and Sanofi. Speaker Honararia for Viatris. AY: Has received research grants from Novartis, MSD, AstraZeneca and Sanofi, and has acted as a speaker/consultant for AstraZeneca, Abdi Ibrahim, GSK, Novartis, Chiesi and Bilim. GS: Honoraria for articles, speaker and advisory boards: ALK, Bayer, Chiesi, GlaxoSmithKline, Haleon, Noucor, Sanofi- Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Vice President and AR lead for EUFOREA, and Chair member Data Monitoring Committees on SLIT for ALK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

**Figure 1**
European Union Parliament Symposium group photo.

See this image and copyright information in PMC

References

1. 2020–2030 Action Plan for the Global Strategy for the Prevention and Control of Non Communicable Diseases. Prevent and Control Cardiovascular Diseases, Cancers, Chronic Respiratory Diseases, Diabetes (2022). Available online at: https://www.who.int/initiatives/global-noncommunicable-diseases-compact-... (Accessed May 05, 2024).
1. Hellings PW, Borrelli D, Pietikainen S, Agache I, Akdis C, Bachert C, et al. European summit on the prevention and self-management of chronic respiratory diseases: report of the European union parliament summit (29 march 2017). Clin Transl Allergy. (2017) 7:49. 10.1186/s13601-017-0186-3 - DOI - PMC - PubMed
1. Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin Transl Allergy. (2016) 6:29. 10.1186/s13601-016-0116-9. Erratum in: Clin Transl Allergy. (2017) 7:5. doi: 10.1186/s13601-016-0135-6 - DOI - PMC - PubMed
1. Diamant Z, Jesenak M, Hanania NA, Heaney LG, Djukanovic R, Ryan D, et al. EUFOREA pocket guide on the diagnosis and management of asthma: an educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients. Respir Med. (2023) 218:107361. 10.1016/j.rmed.2023.107361 - DOI - PubMed
1. Hellings PW, Fokkens WJ, Orlandi R, Adriaensen GF, Alobid I, Baroody FM, et al. The EUFOREA pocket guide for chronic rhinosinusitis. Rhinology. (2023) 61(1):85–9. 10.4193/Rhin22.344 - DOI - PubMed

LinkOut - more resources

Full Text Sources
- Frontiers Media SA
- PubMed Central
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024

Affiliations

Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Miscellaneous